Pharmaceuticals entering Lake Champlain and their combination effects on developing Zebrafish Embryos

Human-derived pharmaceuticals have been identified entering surface waters in the United States through wastewater effluent. While there is ample literature about what each compound alone does to aquatic life, little is known about the effects aquatic life may experience from the exposure to many different pharmaceuticals present in the environment. More specifically, are the combination of pharmaceuticals in the environment more detrimental to aquatic life than each pharmaceutical alone? Zebrafish embryos were used to model what aquatic life in Lake Champlain may experience. Vatovec et al (2016) determined that there are 51 environmentally-relevant human derived pharmaceuticals entering Lake Champlain through wastewater effluent. Out of the 51, acetaminophen, carbamazepine, and diphenhydramine were studied. Embryos were exposed to each pharmaceutical for three days at various concentrations and observed for any developmental defects. The sub-lethal concentration of each pharmaceutical was determined and then this specific concentration was used in subsequent combination experiments. Results indicated that the exposure to all three pharmaceuticals were more detrimental to embryonic development than each pharmaceutical alone. However, when pharmaceuticals were combined in groups of two, one of the groups was more detrimental to embryos than the combination of all three pharmaceuticals. Although concentrations used in this experiment were much higher than that found in the environment, the implications of this study are still important. It is necessary to determine and demonstrate at what concentration pharmaceuticals are detrimental to aquatic life so that environmental concentrations never reach the concentrations used in the current experiment. The outcome of this research stands as a warning as to what may occur if nothing is done about pharmaceuticals entering water sources. Future studies should determine combination effects of pharmaceuticals at environmental concentrations

Removal of emerging pollutants in conventional and microalgae based biotechnology urban wastewater treatment plants

Wastewater treatment plants (WWTPs) reduce portion of the input of pharmaceuticals in aquatic systems, but there is no data available about the elimination of emerging contaminants with microalgae technology. The aim of this work was to determine the average mass flows and concentrations of pharmaceuticals in influents and effluents from two sewages treatment plants using conventional and microalgae based biotechnologies and to compare the removal of pharmaceuticals using both depuration technologies. Only between 20 to 60% of five pharmaceuticals groups is reduce in both WWTP using conventional technologies consisting of a pretreatment, primary settling and secondary treatment by aerobic biological reactor. Using microalgae based biotechnologies efficiency of removal pharmaceuticals is higher than conventional technologies and it increase by using DAF (Dissolve Air Flotation) technology to separate algae biomass

Multi-residue analysis of pharmaceuticals in Belgian surface water : a novel screening-to-quantification approach using large-volume injection liquid chromatography coupled to high-resolution mass spectrometry

The ever growing number of emerging micropollutants such as pharmaceuticals requests rapid and sensitive full-spectrum analytical techniques. Time-of-flight highresolution mass spectrometry (TOF-HRMS) is a promising alternative for the state-ofthe- art MS/MS instruments because of its ability to simultaneously screen towards a virtually unlimited list of suspect compounds and to perform target quantification. The challenge for such suspect screening is to develop a strategy which minimizes the false negative rate without restraining numerous false positives. At the same time, omitting laborious sample enrichment through large-volume injection ultraperformance liquid chromatography (LVI-UPLC) is advantageous avoiding selective preconcentration. A novel suspect screening strategy was developed using LVI-UPLC-TOF-MS aiming the detection of 69 multi-class pharmaceuticals in surface water without the a priori availability of analytical standards. As a novel approach, the screening takes into account the signal intensity-dependent accurate mass error, hereby assuring the detection of 95% of pharmaceuticals present in surface water. Subsequently, the validation and applicability of the full-spectrum method for target quantification of the 69 pharmaceuticals in surface water is discussed. Analysis of five Belgian river water samples revealed the occurrence of 17 pharmaceuticals in a concentration range of 17 ng L-1 up to 3.1 μg L-1

The phytocannabinoid, Δ(9) -tetrahydrocannabivarin, can act through 5-HT1 A receptors to produce antipsychotic effects

Funded by: •GW Pharmaceuticals Acknowledgements: The authors wish to thank Mrs Lesley Stevenson for technical support and Dr John Raymond, Dr Keith Parker and Dr Ethan Russo for providing human 5-HT1A CHO cells. This research was supported by a grant from GW Pharmaceuticals to M. G. C. and R. G. P.Peer reviewedPostprin

IPRs, technological and industrial development and growth: the case of the pharmaceutical industry

Discussion of effects of TRIPs on pharmaceuticals in developing countrie

Neuroprotection in a Novel Mouse Model of Multiple Sclerosis

The authors acknowledge the support of the Barts and the London Charity, the Multiple Sclerosis Society of Great Britain and Northern Ireland, the National Multiple Sclerosis Society, USA, notably the National Centre for the Replacement, Refinement & Reduction of Animals in Research, and the Wellcome Trust (grant no. 092539 to ZA). The siRNA was provided by Quark Pharmaceuticals. The funders and Quark Pharmaceuticals had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Limitations in Predicting Radiation-Induced Pharmaceutical Instability during Long-Duration Spaceflight

As human spaceflight seeks to expand beyond low-Earth orbit, NASA and its international partners face numerous challenges related to ensuring the safety of their astronauts, including the need to provide a safe and effective pharmacy for long-duration spaceflight. Historical missions have relied upon frequent resupply of onboard pharmaceuticals; as a result, there has been little study into the effects of long-term exposure of pharmaceuticals to the space environment. Of particular concern are the long-term effects of space radiation on drug stability, especially as missions venture away from the protective proximity of the Earth. Here we highlight the risk of space radiation to pharmaceuticals during exploration spaceflight, identifying the limitations of current understanding. We further seek to identify ways in which these limitations could be addressed through dedicated research efforts aimed towards the rapid development of an effective pharmacy for future spaceflight endeavors.Comment: in press, Nature Microgravit

Targeted monitoring for human pharmaceuticals in vulnerable source and final waters

A range of pharmaceuticals has been detected in soils, surface waters and groundwaters across the world. While the reported concentrations are generally low (i.e. sub μg l-1 in surface waters), the substances have been observed throughout the year across a variety of hydrological, climatic and land-use settings. As a result, questions have been raised over the potential for pharmaceuticals in surface waters to enter drinking water supplies and to affect consumers. In a previous Drinking Water Inspectorate (DWI) funded study, results from a simple exposure model were used alongside information on therapeutic doses of pharmaceuticals to identify pharmaceuticals that are likely to be of most concern in UK drinking water sources. However, this previous study was entirely desk-based and did not involve any experimental measurements of pharmaceutical concentrations. The current study was therefore performed to generate actual measurements on the occurrence of pharmaceuticals in source and treated waters in England. The study considered a range of pharmaceutical compounds and their metabolites that have either a) high predicted exposure concentrations; b) toxicological concerns; or c) a low predicted exposure to therapeutic dose ratio. An illicit drug and its major metabolite were also investigated. The study compounds (in total 17) covered a range of chemical classes and varied in terms of their physico-chemical properties. The study was done at four sites where concentrations in source water at the drinking water treatment abstraction point were predicted to be some of the greatest in England. The study therefore is likely to provide a ‘worst case’ assessment of potential human exposure to pharmaceuticals in drinking water in England and Wales. Ten of the 17 study compounds were detected in untreated source waters at sub-μg/l concentrations. Six of these compounds (namely, benzoylecgonine (a metabolite of cocaine), caffeine, carbamazepine (an antiepileptic medicine), carbamazepine epoxide (a metabolite of carbamazepine), ibuprofen and naproxen (both non-steroidal anti-inflammatory drugs) were also detected in treated drinking water. With the exception of carbamazepine epoxide, concentrations in treated drinking water were generally significantly lower than in source water. Even though England is a densely populated country and in some regions there is limited dilution of wastewater effluents, these observations, made at sites that were predicted to have some of the highest concentrations of pharmaceuticals in England and Wales, are in line with results from similar studies performed in other countries. Comparison of measured concentrations of the study compounds in drinking waters with information on therapeutic doses demonstrated that levels of these compounds in drinking water in England are many orders of magnitude lower than levels that are given to patients therapeutically. It would therefore appear that the low or non-detectable levels of pharmaceuticals and illicit drugs present in drinking waters in England and Wales do not pose an appreciable risk to human health

Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes : A prospective, real-world, cross-sectional survey of US adult asthma patients and physicians

Date of Acceptance: 26/06/2015 Acknowledgements The disease-specific program, on which the analyses were based, was designed and run by Adelphi Real World. The program was supported by a number of pharmaceutical companies, including Meda Pharmaceuticals. This specific analysis, together with this publication, was supported by Meda Pharmaceuticals. The decision to publish was made jointly by all authors cited. Medical writing support and literature searching was provided by Carole Alison Chrvala, PhD of Health Matters, Inc.Peer reviewedPublisher PD